Compare iShares Core MSCI EAFE ETF (IEFA) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.18 (market cap $189.19B), while Zimmer Biomet Holdings Inc trades at $88.99 (market cap $16.95B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 11.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| IEFA | ZBH | |
|---|---|---|
Market Cap | $189.19B | $16.95B |
Volume | 8,441,787 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $103.98 |
52-Week Low | $85.06 | $79.58 |
Typical Hold Time | 41 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $96.18, down 0.02% on the day, with a bearish technical outlook indicated by moving averages and oscillators. The ETF, managed by BlackRock, holds $196 billion in assets and focuses on developed markets outside North America. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower expense ratio relative to some peers, though performance has lagged behind certain total-world and emerging market funds over the past year.
The outlook for IEFA is clouded by technical weakness and competitive pressures, though its scale and cost efficiency offer stability. Key risks include concentration in developed markets, which may underperform during global growth shifts, and the impact of geopolitical tensions on international equities. Analyst sentiment is mixed, with the fund's defensive characteristics balancing against limited near-term catalysts.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
